Key references: Common health problems in people with fragile X syndrome

  • Aubertin G, Turk J, Levitas A, Visootsak J, Delahunty C, Berry‐Kravis E. Medications for individuals with fragile X syndrome. McLean VA: National Fragile X Clinical and Research Consortium; 2012. https://fragilex.org/our-research/nfxf/treatment-guidelines/
  • Berry-Kravis E, Sumis A, Hervey C, Mathur S. Clinic-based retrospective analysis of psychopharmacology for behavior in fragile x syndrome. Int J Pediatr 2012;2012:843016. https://www.ncbi.nlm.nih.gov/pubmed/22899942
  • Hagerman RJ, Berry-Kravis E, Kaufmann WE, Ono MY, Tartaglia N, Lachiewicz A, et al. Advances in the treatment of fragile X syndrome. Pediatrics 2009;123(1):378–90. https://www.ncbi.nlm.nih.gov/pubmed/19117905
  • Hagerman R, Hagerman P, editors. Fragile X syndrome and premutation disorders: New developments and treatments. London: Mac Keith Press; 2020.
  • National Fragile X Foundation (NFXF). Consensus documents on treatments and interventions for fragile X [online resource]. McLean, VA: NFXF; Accessed June 2019. https://fragilex.org/our-research/nfxf/treatment-guidelines/
  • Nunn KP, Dey C, editors. The clinician’s guide to psychotropic prescribing children and adolescents. Newcastle, NSW: Child & Adolescent Mental Health Statewide Network CAMHSNET; 2003.
  • Tranfaglia MR. A medication guide for fragile X syndrome. 4th ed. Newburyport (MA): FRAXA Research Foundation; 2009. https://www.fraxa.org/guide-to-medication/
  • Wang LW, Berry-Kravis E, Hagerman RJ. Fragile X: leading the way for targeted treatments in autism. Neurother 2010;7(3):264–74. https://www.ncbi.nlm.nih.gov/pubmed/20643379